Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israel, Tel Aviv
Oren Shebolet
61 years of experience
accreditations :
Clinic is certified :
No hidden fees – just official clinic prices. Pay at the clinic for Brain MRI upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Brain MRI and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Brain MRI journey.
Dr. Oren Shibolet is a highly experienced gastroenterologist and hematologist with over 50 years of practice. He is a leading expert in liver conditions and treatments, having served as the Head of the Liver Unit at Sourasky (Ichilov) Medical Center. He has a degree in general medicine from the Hebrew University, a specialty in gastroenterology from the Hebrew University Hadassah Medical School, and is a member of multiple medical organizations. He is also an author of over 60 publications and 100 conference reports.
Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.
He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.